Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9656519 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL8601944 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL8603096 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL7749152 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL8597402 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL7749194 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL11725540 | 0.98 | CASP2 (0.64) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL5947032 | 0.93 | CASP2 (0.52) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL28574271 | 0.88 | CASP2 (0.58) | CASP2NAAAEPHX1MEN1KMT2A | |
| SCHEMBL4068490 | 0.86 | CASP2 (0.71) | CASP2NAAAEPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108689874-A | A kind of method and its application preparing 2- aryl malonamides | 泸州东方农化有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-103131330-B | Composition for polishing and use its Ginding process | FUJIMI INC. (JP) | 2015-09-23 | — | — | CN | disclosed |
| CN-103131330-A | Polishing composition and polishing method using the same | FUJIMI INC | 2013-06-05 | — | — | CN | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7638471-B2 | Transparent cleansing bar comprising flipped N-acyl glutamate | CONOPCO, INC., (US) | 2009-12-29 | — | — | US | disclosed |
| WO-2009071299-A1 | TRANSPARENT CLEANSING BAR | UNILEVER PLC (GB) | 2009-06-11 | — | — | WO | disclosed |
| US-20090149370-A1 | Transparent Cleansing Bar | CONOPCO, INC., D/B/A UNILEVER (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009038031-A1 | BLOCK COPOLYMER AND PRODUCTION PROCESS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038006-A1 | RANDOM COPOLYMER AND PRODUCTION PROCESS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-26 | — | — | WO | disclosed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | disclosed |
| US-7294642-B2 | 1,3-Diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2006101937-A1 | ACYLHYDRAZONES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| WO-1995033813-A1 | IMPROVED DETERGENT COMPOSITION | UNILEVER N.V. (NL) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066610-A1 | Acylhydrazones as kinase modulators | MET, ERBB2, ERBB3 | CASP2 1973/4885NAAA 3840/4885EPHX1 3879/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | CASP2 1112/4885NAAA 484/4885EPHX1 1903/4885 |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | CASP2 1503/4885NAAA 83/4885EPHX1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.